EGFR and KEAS G12C ?
My father was diagnosed almost 2 years ago with Stage IV lung adenocarcinoma (NSCLC) with bone metastases.
At diagnosis which was in June 2024, a liquid biopsy (blood test) that only tested for EGFR mutations came back positive (EGFR L861Q).
A few months later, the tissue biopsy molecular testing showed EGFR wild-type, but identified a KRAS G12C mutation instead.
He was initially treated with osimertinib + chemo for a year although progression started sooner than the one year mark, and later in October 2025 switched to sotorasib after KRAS G12C was confirmed. Sotorasib controlled the disease for about 4–5 months, but he has now developed disease progression.
We are currently waiting for the results of a new comprehensive NGS test to better understand the resistance mechanism.
Has anyone experienced something similar?
EGFR detected on liquid biopsy but EGFR wild-type on tissue biopsy?
Both EGFR and KRAS G12C detected at different times?
What did your repeat NGS show after progression?
What treatment worked next?